← Leaderboards
Balveen Kaur
Ohio State University
$17,543,202
Attributed
$18,078,685
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,078,685 · 15
By mechanism
R01$10,447,969 · 4
P01$3,742,933 · 3
R61$1,545,967 · 2
R21$778,407 · 2
K01$525,633 · 1
R33$385,000 · 1
Top collaborators
- Bangxing B Hong2 shared
- Anne-Marie Carbonell1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Michael A Caligiuri$65,062,344
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorVirusBrain NeoplasmsOncolytic VirusesOncolyticIn VivoNeoplastic CellGliomaTreatment EfficacyViralClinical TrialsCellsMalignant GliomaGlioblastomaModalityToxic EffectMediatingTranslatingMalignant NeoplasmsBrainExtracellularGrantResponseIn Vitro
Grant awards (61)
Next generation oncolytic virotherapy targeting AKT and ERK signaling in glioma$550,350
R01 · FY2025 · NS · contact PI
Next Gen Virotherapy for GBM$529,564
R01 · FY2025 · NS · contact PI
Development of murine glioblastoma model for oncolytic HSV therapy$375,155
R61 · FY2025 · NS · contact PI
Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy$267,107
P01 · FY2025 · CA · contact PI
Next generation oncolytic virotherapy targeting AKT and ERK signaling in glioma$563,850
R01 · FY2024 · NS · contact PI
Next Gen Virotherapy for GBM$513,678
R01 · FY2024 · NS · contact PI
Development of murine glioblastoma model for oncolytic HSV therapy$395,812
R61 · FY2024 · NS · contact PI
Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy$253,752
P01 · FY2024 · CA · contact PI
Next Gen Virotherapy for GBM$529,564
R01 · FY2023 · NS · contact PI
Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy$306,607
P01 · FY2023 · CA · contact PI
Next Gen Virotherapy for GBM$536,442
R01 · FY2022 · NS · contact PI
Optimizing oncolytic virus therapy for glioblastoma$385,000
R33 · FY2022 · NS · contact PI
Project 3: Notch signaling in oHSV therapy for GBM$314,231
P01 · FY2022 · CA · contact PI
Project 3: Notch signaling in oHSV therapy for GBM$320,643
P01 · FY2021 · CA · contact PI
Optimizing oncolytic virus therapy for glioblastoma$390,000
R61 · FY2020 · NS · contact PI
Enhancing viral oncolysis with vasculostatin gene delivery$372,323
R01 · FY2020 · CA · contact PI
Project 3: Notch signaling in oHSV therapy for GBM$320,643
P01 · FY2020 · CA · contact PI
Optimizing oncolytic virus therapy for glioblastoma$385,000
R61 · FY2019 · NS · contact PI
Enhancing viral oncolysis with vasculostatin gene delivery$362,675
R01 · FY2019 · CA · contact PI
Project 3: Notch signaling in oHSV therapy for GBM$311,024
P01 · FY2019 · CA · contact PI
Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma$300,000
R41 · FY2019 · CA
Enhancing viral oncolysis with vasculostatin gene delivery$382,987
R01 · FY2018 · CA · contact PI
Project 3: Notch signaling in oHSV therapy for GBM$340,395
P01 · FY2018 · CA · contact PI
OV therapy induced changes in tumor secretome and their impact on therapy$324,270
R01 · FY2018 · NS · contact PI
OV therapy induced changes in tumor secretome and their impact on therapy$336,875
R01 · FY2017 · NS · contact PI
Enhancing viral oncolysis with vasculostatin gene delivery$336,268
R01 · FY2017 · CA · contact PI
The Tumor Microenvironmental Barrier to Effective Viral Oncolysis$255,024
P01 · FY2017 · CA · contact PI
Enhancing viral oncolysis with vasculostatin gene delivery$64,775
R01 · FY2017 · CA · contact PI
Enhancing viral oncolysis with vasculostatin gene delivery$398,182
R01 · FY2016 · CA · contact PI
OV therapy induced changes in tumor secretome and their impact on therapy$336,875
R01 · FY2016 · NS · contact PI
The Tumor Microenvironmental Barrier to Effective Viral Oncolysis$251,643
P01 · FY2016 · CA · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$410,429
R01 · FY2015 · CA · contact PI
OV therapy induced changes in tumor secretome and their impact on therapy$336,875
R01 · FY2015 · NS · contact PI
The Tumor Microenvironmental Barrier to Effective Viral Oncolysis$246,137
P01 · FY2015 · CA · contact PI
Ohio State Neuroscience Center Core$72,710
P30 · FY2015 · NS · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$395,103
R01 · FY2014 · CA · contact PI
OV therapy induced changes in tumor secretome and their impact on therapy$336,602
R01 · FY2014 · NS · contact PI
The Tumor Microenvironmental Barrier to Effective Viral Oncolysis$238,568
P01 · FY2014 · CA · contact PI
Ohio State Neuroscience Center Core$61,869
P30 · FY2014 · NS · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$380,007
R01 · FY2013 · CA · contact PI
The Tumor Microenvironmental Barrier to Effective Viral Oncolysis$317,159
P01 · FY2013 · CA · contact PI
Ohio State Neuroscience Center Core$70,478
P30 · FY2013 · NS · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$41,772
R01 · FY2013 · CA · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$401,253
R01 · FY2012 · CA · contact PI
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy$312,375
R01 · FY2012 · NS · contact PI
Ohio State Neuroscience Center Core$72,728
P30 · FY2012 · NS · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$31,151
R01 · FY2012 · CA · contact PI
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery$398,286
R01 · FY2011 · CA · contact PI
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy$312,375
R01 · FY2011 · NS · contact PI
Ohio State Neuroscience Center Core$74,991
P30 · FY2011 · NS · contact PI
Combination of Cliengitide and Oncolytic HSV: a toxicology study for brain tumors$54,436
K01 · FY2011 · NS · contact PI
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy$315,563
R01 · FY2010 · NS · contact PI
Enhancement of Viral Spread by Modulation of Glioma Extracellular Matrix$188,719
R21 · FY2010 · NS · contact PI
Combination of Cliengitide and Oncolytic HSV: a toxicology study for brain tumors$160,126
K01 · FY2010 · NS · contact PI
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy$318,750
R01 · FY2009 · NS · contact PI
Enhancement of Viral Spread by Modulation of Glioma Extracellular Matrix$228,750
R21 · FY2009 · NS · contact PI
Combination of Cliengitide and Oncolytic HSV: a toxicology study for brain tumors$157,036
K01 · FY2009 · NS · contact PI
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy$318,750
R01 · FY2008 · NS · contact PI
Oncolytic HSV Cancer Therapy: Enhancement by Vasculostatin Gene Therapy$164,063
R21 · FY2008 · NS · contact PI
Combination of Cliengitide and Oncolytic HSV: a toxicology study for brain tumors$154,035
K01 · FY2008 · NS · contact PI
Oncolytic HSV Cancer Therapy: Enhancement by Vasculostatin Gene Therapy$196,875
R21 · FY2007 · NS · contact PI